| __timestamp | Amphastar Pharmaceuticals, Inc. | Ascendis Pharma A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 6274000 |
| Thursday, January 1, 2015 | 46974000 | 9415000 |
| Friday, January 1, 2016 | 47298000 | 11504000 |
| Sunday, January 1, 2017 | 50918000 | 13482000 |
| Monday, January 1, 2018 | 58044000 | 25057000 |
| Tuesday, January 1, 2019 | 63109000 | 48473000 |
| Wednesday, January 1, 2020 | 65157000 | 76669000 |
| Friday, January 1, 2021 | 68920000 | 160180000 |
| Saturday, January 1, 2022 | 66592000 | 221227000 |
| Sunday, January 1, 2023 | 80393000 | 264410000 |
| Monday, January 1, 2024 | 284545000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Ascendis Pharma A/S and Amphastar Pharmaceuticals, Inc. have shown contrasting trends in their SG&A costs. From 2014 to 2023, Ascendis Pharma A/S experienced a staggering increase of over 4,100%, with expenses rising from approximately $6.3 million to $264 million. This growth reflects their aggressive expansion and investment in new markets. In contrast, Amphastar Pharmaceuticals, Inc. saw a more modest increase of about 99%, from $40 million to $80 million, indicating a steady, controlled growth strategy. These trends highlight the different strategic approaches of these companies in navigating the pharmaceutical landscape. As the industry evolves, monitoring such financial metrics will be key to understanding the future trajectories of these pharma giants.
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Incyte Corporation and Ascendis Pharma A/S
Who Optimizes SG&A Costs Better? Dr. Reddy's Laboratories Limited or Ascendis Pharma A/S
Ascendis Pharma A/S and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared
Ascendis Pharma A/S or Xenon Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Ascendis Pharma A/S and PTC Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Galapagos NV
Ascendis Pharma A/S or Evotec SE: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.